BACKGROUND: Limited French data are available for the different clinical types (paroxysmal, persistent and permanent) of atrial fibrillation and their comorbidities (AF). AIMS: To provide contemporary insights into the characteristics and management of outpatients with a history of or current AF in France. METHODS: EPHA is a national, observational, cross-sectional, multicentre descriptive study with retrospective data collection relating to the management, treatment and hospitalization of patients with AF. RESULTS: One thousand three hundred and thirty-one patients (mean age: 74 +/- 11 years [55.7% > or =75 years]; 58.8% men) were included into the study between February 2009 and May 2009; their data were collected during the past 12 months. Of these, 38.2% had paroxysmal AF, 10.0% persistent AF and 51.8% permanent AF. Most patients had at least one cardiovascular risk factor (80.8%). Almost all patients (96.6%) had received an antiarrhythmic drug in the previous year, of which 59.6% received a rhythm control strategy (class I, class III) with or without rate control strategy (class II, class IV, digitalis) and 40.6% received a rate control strategy exclusively. Almost all (94.4%) patients were treated with an antithrombotic: 83.4% with a vitamin K antagonist and 21.9% with antiplatelet therapy. Almost one-fifth (18.4%) of patients had been hospitalized related to AF at least once in the previous year. Patients with paroxysmal and persistent AF were hospitalized more frequently (20.0% and 31.1%, respectively) than patients with permanent AF (14.8%). CONCLUSIONS: About half of the patients had paroxysmal or persistent AF. Four-fifths of AF patients had at least one cardiovascular risk factor. The use of antiarrhythmic and antithrombotic treatments was very high. The rhythm control strategy was preferred in patients with paroxysmal or persistent AF. Copyright 2010. Published by Elsevier Masson SAS.
BACKGROUND: Limited French data are available for the different clinical types (paroxysmal, persistent and permanent) of atrial fibrillation and their comorbidities (AF). AIMS: To provide contemporary insights into the characteristics and management of outpatients with a history of or current AF in France. METHODS: EPHA is a national, observational, cross-sectional, multicentre descriptive study with retrospective data collection relating to the management, treatment and hospitalization of patients with AF. RESULTS: One thousand three hundred and thirty-one patients (mean age: 74 +/- 11 years [55.7% > or =75 years]; 58.8% men) were included into the study between February 2009 and May 2009; their data were collected during the past 12 months. Of these, 38.2% had paroxysmal AF, 10.0% persistent AF and 51.8% permanent AF. Most patients had at least one cardiovascular risk factor (80.8%). Almost all patients (96.6%) had received an antiarrhythmic drug in the previous year, of which 59.6% received a rhythm control strategy (class I, class III) with or without rate control strategy (class II, class IV, digitalis) and 40.6% received a rate control strategy exclusively. Almost all (94.4%) patients were treated with an antithrombotic: 83.4% with a vitamin K antagonist and 21.9% with antiplatelet therapy. Almost one-fifth (18.4%) of patients had been hospitalized related to AF at least once in the previous year. Patients with paroxysmal and persistent AF were hospitalized more frequently (20.0% and 31.1%, respectively) than patients with permanent AF (14.8%). CONCLUSIONS: About half of the patients had paroxysmal or persistent AF. Four-fifths of AFpatients had at least one cardiovascular risk factor. The use of antiarrhythmic and antithrombotic treatments was very high. The rhythm control strategy was preferred in patients with paroxysmal or persistent AF. Copyright 2010. Published by Elsevier Masson SAS.
Authors: O Hanon; J S Vidal; G Pisica-Donose; L Benattar-Zibi; P Bertin; G Berrut; E Corruble; G Derumeaux; B Falissard; F Forette; F Pasquier; M Pinget; R Ourabah; L Becquemont; N Danchin Journal: J Nutr Health Aging Date: 2015-02 Impact factor: 4.075
Authors: Mary P Panaccio; Gordon Cummins; Charles Wentworth; Stephan Lanes; Shannon L Reynolds; Matthew W Reynolds; Raymond Miao; Andrew Koren Journal: Clin Epidemiol Date: 2015-01-12 Impact factor: 4.790
Authors: Jan Murin; Lisa Naditch-Brûlé; Sandrine Brette; Chern-En Chiang; James O'Neill; P Gabriel Steg Journal: PLoS One Date: 2014-01-31 Impact factor: 3.240